2592.HK

Ophthalmic biotech company Cloudbreak Pharma Inc. (2592.HK) opened down 6% in its Hong Kong trading debut on Wednesday, and continued to fall during the morning session to close down 30% at HK$7.04 by the midday break.

The company sold 60.58 million shares for HK$10.10 apiece to raise net proceeds of about HK$ 522 million ($66 million). The public offering for local Hong Kong investors was oversubscribed by 78 times, while the international placement was undersubscribed.

Cloudbreak recorded no revenue in 2022 or 2023, and booked just $10 million in 2024. Its net loss last year stood at $99.13 million, narrower by 23% year-on-year.

By Lau Chi Hang

To subscribe to Bamboo Works weekly free newsletter, clickhere

Recent Articles

New Gonow earnings

Dwindling sales of luxury RVs stall New Gonow earnings

The Chinese motorhome maker has announced plans for a temporary retreat from the top-tier RV market after delivering weak half-year results Key Takeaways: New Gonow’s revenue fell 2.4% and its…